EP0925310B1 - Utilisation de polysaccharides sulfates dans le traitement de plaies chroniques - Google Patents
Utilisation de polysaccharides sulfates dans le traitement de plaies chroniques Download PDFInfo
- Publication number
- EP0925310B1 EP0925310B1 EP97939097A EP97939097A EP0925310B1 EP 0925310 B1 EP0925310 B1 EP 0925310B1 EP 97939097 A EP97939097 A EP 97939097A EP 97939097 A EP97939097 A EP 97939097A EP 0925310 B1 EP0925310 B1 EP 0925310B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sulfated
- polysaccharide
- use according
- cellulose
- orc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
Definitions
- the present invention relates to the use of sulfated polysaccharides obtained by sulfation of cellulose derivatives or polyanionic polysaccharides and uses thereof in pharmaceutical and wound treatment compositions.
- Sulfated saccharide and polysaccharide derivatives in which one or more hydroxyl groups on individual saccharide residues are replaced by sulfate groups, are known.
- Such sulfated saccharides can occur naturally, as in the case of the sulfated glucosaminoglycans such as heparan sulfate and chondroitin sulfate.
- Other sulfated saccharides, oligosaccharides and polysaccharides have been prepared by sulfation of naturally occurring saccharides, oligosaccharides or polysaccharides.
- sucrose octasulfate obtained by sulfation of sucrose.
- sucralfate insoluble aluminum salt of sucrose octasulfate
- US-A-2697093 describes the sulfation of cellulose, inulin, starch or dextrin with sulfur trioxide-tertiary amine reagents.
- the resulting sulfated materials are stated to be useful as thickeners for paste, adhesives, and additives for muds used in drilling oil wells.
- Certain sulfated polysaccharides, and in particular the sulfated glucosaminoglycans, are used in medicine as anticoagulants.
- heparin a highly polydisperse copolymer of 1-4 linked glucosamine and uronic acid residues, plays an important role in the control of blood coagulation. Heparin binds the serine protease inhibitor antithrombin producing a complex which accelerates the proteolysis of the enzyme responsible for coagulation.
- the anticoagulant properties of heparin and its analogs have been known for some time and have been usefully applied in the biomedical field.
- the preparation of heparin and sulfated glucosaminoglycans from natural sources is expensive, and therefore an alternative is desirable.
- cellulose derivative encompasses any biologically acceptable ester, ether, hydrolysis product or oxidation product of cellulose.
- Preferred cellulose derivatives include carboxymethyl cellulose, hydroxyethyl cellulose, cellulose acetate and, especially, oxidized cellulose derivatives such as oxidized regenerated cellulose (ORC), or the oxidized cellulose ethers and esters described and claimed in the provisional US patent application USSN 60/020,758 assigned to the same assignee as the present application and filed on 28th June 1996 and entitled "Bioresorbable Medical Devices from Oxidized Cellulose Derivatives".
- Preferred materials are obtained by oxidation of hydroxyethyl cellulose, carboxymethyl cellulose or cellulose acetate with dinitrogen tetroxide. The most preferred material is oxidized regenerated cellulose (ORC).
- polyanionic polysaccharide encompasses any biologically acceptable polysaccharide in which a plurality of the saccharide residues in each polysaccharide molecule comprise an anionic group such as carboxylate, or the complementary acid or salt of such an anionic group. It will be appreciated that some of the cellulose derivatives defined above will also be polyanionic polysaccharides. Preferred polyanionic polysaccharides include alginates, pectins, hyaluronic acid, oxidized starch and oxidized cellulose derivatives as described above. Most preferably, the polyanionic polysaccharide is an alginate.
- Naturally occurring sulfated polyanionic polysaccharides such as chondroitin sulfate are not included within the scope of the present invention, which relates only to synthetic (i.e. chemically sulfated) polysaccharide derivatives.
- Oxidised regenerated cellulose is a well known cellulose derivative that is prepared from cellulose as described in US-A-3122479. Oxidation of the primary hydroxyl groups of cellulose to carboxylate groups results in a polyanionic cellulose derivative, namely ORC.
- ORC is known and used in the biomedical field as a haemostatic agent, as described in US-A-2517772. It is commercially available in the form of a fabric under the registered trade mark Surgicel (Johnson & Johnson Medical, Inc.), and as a haemostatic wound treatment composition under the registered trade mark Interceed (Johnson & Johnson Medical, Inc.). It has been found that ORC is both haemostatic and fully bioabsorbable, and thus provides important advantages as a wound dressing material.
- alginate used herein encompasses alginic acid, soluble salts thereof such as sodium alginate, and insoluble salts thereof such as calcium alginate.
- the alginate is calcium alginate, which is available for use in wound dressings under the Registered Trade Marks Instat (Johnson & Johnson Medical, Inc.) and Kaltostat (E.R. Squibb & Sons, Inc.).
- the alginate has a molecular weight in the range 50,000 to 400,000 and a mannuronic acid/guluronic acid ratio of about 0.45.
- the sulfated polysaccharides used in the present invention differ from the non-sulfated base materials in that at least some of the hydroxyl groups on the saccharide residues of the polysaccharides have been converted to sulfate groups.
- an average of at least 0.1 hydroxyl groups on each saccharide residue have been converted to sulfate groups. More preferably, at least 1 hydroxyl group, on average, on each saccharide residue has been converted to sulfate groups, and most preferably from 3 to 4 hydroxyl groups on each saccharide residue have been so converted.
- the sulfated polysaccharides can exist in the free acid form, but will more normally be used in the form of a salt or hydrate.
- the salt may be a salt with an alkali metal cation such as sodium or potassium, or may be a salt formed with polyvalent ions such as calcium or aluminum (by analogy with sucralfate), or may be a salt formed with complex cations such as ammonium or alkylammonium.
- the sulfated polysaccharide or its soluble salts may be stored or used in the form of a buffered aqueous solution.
- the term "sulfated polysaccharide" in the present specification encompasses all such salts and hydrates.
- the sulfated polysaccharides can be made with substantially any molecular weight from 500 to 5,000,000, depending on the molecular weight of the starting material.
- Low molecular weight sulfated polysaccharides generally have alkali metal salts that are soluble in water, and accordingly such materials having molecular weights in the range 1,000 - 50,000 are preferred for some applications. These materials preferably have solubility of at least 10g/l, more preferably at least 25g/l in water at pH7.
- the base polysaccharide preferably has an average molecular weight in the range 50,000 - 250,000, more preferably 50,000 - 150,000.
- sulfated polysaccharides and/or their salts are usually Substantially insoluble in water.
- insoluble sulfated ORC can be prepared from commercially available fibrous ORC in the form of a woven, non-woven or knitted fabric, thereby providing a sulfated ORC in the form of a fabric.
- the present invention provides a pharmaceutical composition comprising a sulfated cellulose derivative and/or a sulfated anionic polysaccharide.
- pharmaceutical composition includes wound treatment compositions and wound dressings and implants, as well as topical, oral or parenteral medicinal compositions.
- MMP matrix metalloproteinases
- the present invention further provides the use of a sulfated polysaccharide for the preparation of a composition for the treatment of medical conditions mediated by a matrix metalloproteinase.
- the medical condition is a wound, especially a chronic wound or ulcer.
- This aspect of the invention further encompasses the use of a pharmaceutical composition containing the sulfated polysaccharide, preferably together with conventional pharmaceutical excipients, for the treatment of a chronic wound such as a venous ulcer or a decubitis ulcer in a mammal by the topical or systemic administration thereof.
- the sulfated oligosaccharide is applied topically as or in a wound dressing composition.
- the sulfated polysaccharide is applied in an ointment containing 0.1%-10% w/w of the sulfated polysaccharide together with conventional excipients such as water and a gelling agent.
- compositions according to the present invention may further comprise conventional pharmaceutical excipients and/or other active agents. They may be adapted for topical, oral or parenteral administration.
- the sulfated anionic polysaccharides can be prepared by sulfation of a cellulose derivative or a polyanionic polysaccharide with sulfur trioxide-tertiary amine complexes or sulfur trioxidepyridine complexes in a suitable inert polar solvent, such as N-methyl pyrrolidone.
- the degree of sulfation can be controlled by adjusting the molar ratio of polysaccharide to sulfur trioxide, since the reaction is essentially quantitative.
- the extend of sulfation can be monitored by nmr and elemental analysis, and in particular by Infrared spectroscopy.
- the sulfation is preferably carried out on a low molecular weight, soluble oligosaccharide.
- the sulfation can be carried out on ORC oligosaccharides obtained as described in the present applicant's co-pending United Kingdom patent application no. 9613683.3 entitled "Oxidised Oligosaccharides". Briefly, the ORC oligosaccharides are prepared by treating commercially available ORC with 6M sodium hydroxide solution at 37°C for 45 minutes, followed by filtration. The filtrate containing the ORC oligosaccharides in solution is subjected to neutralisation and dialysis to remove fragments and impurities having molecular weight below 1000, and is then freeze-dried.
- Milled ORC (Interceed®, lOg) was activated by slurrying in 100ml deionised water with stirring for 40 minutes at 40°C. The slurry was filtered using a Buchner apparatus, and the resultant cake was resuspended in 100ml glacial acetic acid and stirred for a further 30 minutes at 4°C to remove any excess water. The slurry was again filtered and washed extensively with N-methyl pyrrolidone (NMP) until all the acetic acid was removed.
- NMP N-methyl pyrrolidone
- Pyridine sulfur trioxide (40g) was dissolved in 40ml N-methyl pyrrolidone, cooled to 4°C, and slowly added to the activated ORC. The slurry was stirred at 4°C for 2 hours, and the pH was then adjusted to 5.6 by the careful addition of cold 2M NaOH. The neutralised slurry was poured into three volumes of methanol and the precipitate collected. The sulfated material was washed with several portions of methanol to remove the N-methyl pyrrolidone before being washed with distilled water to remove unbound sodium sulfate. The material was frozen and freeze-dried.
- FT-IR analysis of the material revealed that the all of the primary hydroxyl groups and one or more of the secondary hydroxyl groups had been sulfated.
- the product is the insoluble sodium salt of the sulfated ORC.
- Example 1 The procedure of Example 1 was repeated on a lOg sample of Interceed® ORC fabric, resulting in a sulfated ORC fabric product.
- a composite material consisting of a complex between the sulfated ORC according to the present invention and collagen was prepared as follows.
- Sulfated ORC fibres (0.875g) prepared as in Example 1 were suspended in 10ml distilled 0.06M acetic acid and stirred until fully dispersed.
- Bovine collagen which was fully limed, freeze-dried and milled to lmm fibers (1.625g) was slurried in 250ml 0.05M acetic acid and homogenised for 15 seconds on a Waring Blendor.
- the suspension of sulfated ORC was added to the collagen slurry, and the mixture was homogenised for a further 15 seconds.
- the slurry was crosslinked by the addition of 0.0325ml of HMDI, followed by homogenisation for 2 x 15 seconds.
- the slurry was degassed under vacuum, poured into 9cm by 9cm petri dishes, frozen and freeze-dried.
- the resultant sponges were sterilised with gamma-irradiation.
- a sulfated calcium alginate was prepared from Alginic acid supplied by Sigma Chemical Company (A7003). A sample of this material (10g) was sulfated as described in Example 1.
- a composite material consisting of a complex between the sulfated alginate obtained in Example 4 and collagen was prepared by the procedure described in Example 3, using milled sulfated alginate fibers in place of the sulfated ORC fibers.
- MMP matrix metalloproteinase
- Sulfated ORC was prepared by the procedure described in Example 2. An ORC-free collagen sponge was prepared for comparison purposes. A sample of Surgicel® ORC fabric was also prepared for comparison.
- Acute wound fluid contains various proteinases, including matrix metalloproteinases and many of these enzymes will preferentially bind to various dressing materials.
- the excess fluid absorbed by each material was mechanically expressed using a metal spatula and discarded.
- the remaining dressings were placed into pre-packed 2ml syringes (each syringe contained 0.5ml volume of 2.5mm glass beads).
- sample buffer 20 microliters was taken from each container and subjected to gelatin substrate SDS-polyacrylamide gel electrophoresis (zymography) as described by Heussen C. and Dowdle E.B. in Anal. Biochem. 102:196-202 (1980).
- Pro2 and Pro9 are the proenzyme forms of MMP2 and MMP9. Both MMP2 and MMP9 can exist as active an proenzyme forms.
- the molecular weight of the proMMP9 or pro9 is 92kDa.
- MMP activation is a two step process, a conformational change occurs in the proenzyme, followed by removal of the propeptide by a series of autocatalytic changes.
- the molecular weight of the resultant active forms being 86kDa for ActMMP9 and 66kDa for ActMMp2, sometimes called ACT9 and ACT2 for short.
- Procedure 1 was repeated on the following samples: a pure collagen sponge (comparative experiment), collagen/calcium alginate sponges containing 5% and 20% w/w of alginate (comparative experiments identified as 5% ALG and 20% ALG), and collagen/sulfated calcium alginate sponges containing 5%, 10% and 20% w/w of sulfated calcium alginate, prepared as described in Example 5 and identified as 5% SALG, 10% SALG and 20% SALG.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Claims (11)
- Utilisation d'un polysaccharide sulfaté chimiquement choisi parmi les dérivés cellulosiques sulfatés et les polysaccharides polyanioniques chimiquement sulfatés pour la préparation d'une composition pour le traitement d'une plaie chronique.
- Utilisation selon la revendication 1, dans laquelle on choisit le polysaccharide sulfaté parmi les hydroxyéthylcellulose sulfatée, carboxyméthylcellulose sulfatée et cellulose régénérée oxydée sulfatée.
- Utilisation selon la revendication 2, dans laquelle le polysaccharide sulfaté est la cellulose régénérée oxydée sulfatée.
- Utilisation selon la revendication 1, dans laquelle on choisit le polysaccharide sulfaté parmi les alginates sulfatés, les pectines sulfatées et l'acide hyaluronique sulfaté.
- Utilisation selon la revendication 4, dans laquelle le polysaccharide sulfaté est un alginate sulfaté.
- Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le polysaccharide sulfaté comprend une moyenne d'au moins 0,1 groupe sulfate pour chaque résidu saccharide du polysaccharide.
- Utilisation selon la revendication 6, dans laquelle le polysaccharide sulfaté comprend une moyenne d'au moins 1 groupe sulfate pour chaque résidu saccharide du polysaccharide.
- Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le polysaccharide sulfaté a une masse moléculaire moyenne dans la gamme de 25.000 à 250.000.
- Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le polysaccharide sulfaté est sous forme d'un textile tissé, non tissé ou tricoté.
- Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le polysaccharide sulfaté est sous forme d'un complexe solide avec du collagène.
- Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le polysaccharide sulfaté est soluble dans l'eau à un degré d'au moins 10 g/l à 25°C.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9618958A GB2317182B (en) | 1996-09-11 | 1996-09-11 | Sulfated polysaccharides and uses thereof in medical treatment |
GB9618958 | 1996-09-11 | ||
PCT/GB1997/002477 WO1998011141A1 (fr) | 1996-09-11 | 1997-09-10 | Polysaccharides sulfates et leurs utilisations dans les traitements medicaux |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0925310A1 EP0925310A1 (fr) | 1999-06-30 |
EP0925310B1 true EP0925310B1 (fr) | 2000-08-16 |
Family
ID=10799755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97939097A Expired - Lifetime EP0925310B1 (fr) | 1996-09-11 | 1997-09-10 | Utilisation de polysaccharides sulfates dans le traitement de plaies chroniques |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090227537A1 (fr) |
EP (1) | EP0925310B1 (fr) |
JP (1) | JP2001500184A (fr) |
KR (1) | KR20000036061A (fr) |
AU (1) | AU726555B2 (fr) |
BR (1) | BR9711747A (fr) |
CA (1) | CA2265780C (fr) |
DE (1) | DE69702862T2 (fr) |
DK (1) | DK0925310T3 (fr) |
ES (1) | ES2152107T3 (fr) |
GB (1) | GB2317182B (fr) |
NO (1) | NO991160L (fr) |
PT (1) | PT925310E (fr) |
WO (1) | WO1998011141A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10226481B2 (en) | 2011-03-23 | 2019-03-12 | University Of Utah Research Foundation | Pharmaceutical compositions composed of low molecular weight sulfated hyaluronan |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
WO2000056283A1 (fr) * | 1999-03-24 | 2000-09-28 | The B.F.Goodrich Company | Inhibition des metalloproteinases matrices par des polymeres et applications pharmaceutiques correspondantes |
DE10050870A1 (de) * | 2000-10-11 | 2002-08-01 | Knoell Hans Forschung Ev | Biokompatibles Verbundmaterial für medizinische Anwendungen |
EP1711595B1 (fr) * | 2003-12-02 | 2007-11-21 | Universiteit Gent | Utilisation d'alginate polysulfate pour matrices cellulaires |
DE102006024748A1 (de) * | 2006-05-26 | 2007-11-29 | Paul Hartmann Ag | Proteasen-Inhibitor zur Wundbehandlung |
DE102007035322B4 (de) | 2007-07-25 | 2011-11-17 | Friedrich-Schiller-Universität Jena | Verfahren zur Herstellung wasserlöslicher, niedrig substituierter Cellulosesulfate |
CN102177180A (zh) | 2008-04-04 | 2011-09-07 | 犹他州大学研究基金会 | 烷基化半合成的糖胺聚糖醚及其制备和使用方法 |
IT1397246B1 (it) * | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica |
EP2699626A4 (fr) * | 2011-04-11 | 2014-10-29 | Univ Massachusetts Medical | Mailles fibreuses de cellulose modifiées chimiquement pour une utilisation en tant qu'échafaudages d'ingénierie tissulaire |
CN103360499B (zh) * | 2012-04-11 | 2017-02-08 | 厦门大学 | 一种纤维素硫酸酯的简便合成工艺 |
CN104277130A (zh) | 2013-07-02 | 2015-01-14 | 中国科学院上海药物研究所 | 一种硫酸酯化聚古洛糖酸多糖或其可药用盐及其制备方法和用途 |
JP2017524655A (ja) * | 2014-05-23 | 2017-08-31 | レポネックス・ファーマシューティカルズ・エーピーエス | 創傷の治癒を促進するための組成物 |
EP3171887A1 (fr) | 2014-07-24 | 2017-05-31 | Reponex Pharmaceuticals APS | Compositions comprenant le facteur de stimulation des colonies de granulocytes-macrophages pour le traitement d'une maladie inflammatoire de l'intestin |
US11337994B2 (en) | 2016-09-15 | 2022-05-24 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
US11491199B1 (en) | 2021-06-09 | 2022-11-08 | King Abdulaziz University | Anticoagulation activity of sulfated carboxymethyl cellulose/Azadirachta indica leaf powder-based biocomposites |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1056772A (fr) * | 1950-06-23 | 1954-03-02 | Procédé de préparation d'un anticoagulant de synthèse | |
US3115488A (en) * | 1960-02-29 | 1963-12-24 | American Home Prod | Alginic acid methyl ester sulfates, preparation and molecular weight fractionation thereof |
FR1730M (fr) * | 1962-01-17 | 1963-03-18 | Charles Riviere | Nouvelle composition de collyre. |
JPS4943937B1 (fr) * | 1970-12-28 | 1974-11-25 | ||
US3709877A (en) * | 1972-03-07 | 1973-01-09 | Johnson & Johnson | Process for the sulfation of cellulosic ethers |
US3804092A (en) * | 1973-01-15 | 1974-04-16 | Johnson & Johnson | Water dispersible nonwoven fabric |
JPS5152484A (en) * | 1974-10-18 | 1976-05-10 | Sumitomo Chemical Co | Pururanno ryusanesuteru oyobi sono enruino seizohoho |
US4500519A (en) * | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
GB2148901A (en) * | 1983-10-04 | 1985-06-05 | Johnson & Johnson | Protein/polysaccharide complexes |
US4879282A (en) * | 1987-03-17 | 1989-11-07 | Saliba Jr Michael J | Medical application for heparin and related molecules |
JPH02178229A (ja) * | 1988-12-28 | 1990-07-11 | Fujirebio Inc | 抗ウイルス剤 |
ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
US5997863A (en) * | 1994-07-08 | 1999-12-07 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
-
1996
- 1996-09-11 GB GB9618958A patent/GB2317182B/en not_active Expired - Fee Related
-
1997
- 1997-09-10 BR BR9711747A patent/BR9711747A/pt not_active Application Discontinuation
- 1997-09-10 EP EP97939097A patent/EP0925310B1/fr not_active Expired - Lifetime
- 1997-09-10 JP JP10513387A patent/JP2001500184A/ja not_active Ceased
- 1997-09-10 DE DE69702862T patent/DE69702862T2/de not_active Expired - Lifetime
- 1997-09-10 KR KR1019997002065A patent/KR20000036061A/ko not_active Application Discontinuation
- 1997-09-10 WO PCT/GB1997/002477 patent/WO1998011141A1/fr not_active Application Discontinuation
- 1997-09-10 ES ES97939097T patent/ES2152107T3/es not_active Expired - Lifetime
- 1997-09-10 CA CA002265780A patent/CA2265780C/fr not_active Expired - Fee Related
- 1997-09-10 DK DK97939097T patent/DK0925310T3/da active
- 1997-09-10 PT PT97939097T patent/PT925310E/pt unknown
- 1997-09-10 AU AU41315/97A patent/AU726555B2/en not_active Ceased
-
1999
- 1999-03-10 NO NO991160A patent/NO991160L/no not_active Application Discontinuation
-
2009
- 2009-05-13 US US12/465,106 patent/US20090227537A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10226481B2 (en) | 2011-03-23 | 2019-03-12 | University Of Utah Research Foundation | Pharmaceutical compositions composed of low molecular weight sulfated hyaluronan |
Also Published As
Publication number | Publication date |
---|---|
BR9711747A (pt) | 1999-08-24 |
NO991160L (no) | 1999-05-10 |
US20090227537A1 (en) | 2009-09-10 |
AU726555B2 (en) | 2000-11-09 |
GB2317182B (en) | 2000-11-01 |
JP2001500184A (ja) | 2001-01-09 |
PT925310E (pt) | 2000-11-30 |
ES2152107T3 (es) | 2001-01-16 |
KR20000036061A (ko) | 2000-06-26 |
CA2265780A1 (fr) | 1998-03-19 |
GB2317182A (en) | 1998-03-18 |
WO1998011141A1 (fr) | 1998-03-19 |
DE69702862T2 (de) | 2001-02-22 |
EP0925310A1 (fr) | 1999-06-30 |
CA2265780C (fr) | 2006-08-22 |
NO991160D0 (no) | 1999-03-10 |
DK0925310T3 (da) | 2000-11-20 |
GB9618958D0 (en) | 1996-10-23 |
AU4131597A (en) | 1998-04-02 |
DE69702862D1 (de) | 2000-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090227537A1 (en) | Sulfated polysaccharides and uses thereof in medical treatment | |
EP0356435B1 (fr) | Composes et compositions anti-inflammatoires | |
US5767269A (en) | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics | |
EP1325754B1 (fr) | Pansements pour blessures à base de collagène et de cellulose oxydée | |
US4990502A (en) | Low molecular weight heparins of regular structure, their preparation and their biological uses. | |
CA2279535C (fr) | Le bisulfate de dermatan, inhibiteur de la production de thrombine, et de l'activation du complement | |
CA2217054C (fr) | Compositions et procedes destines a inhiber la thrombogenese | |
WO1998014481A9 (fr) | Procedes de preparation d'heparines a faible affinite et a faible masse molaire utiles en tant qu'antithrombotiques | |
US5763427A (en) | Compositions and methods for inhibiting thrombogenesis | |
EP0735050B1 (fr) | Compositions pour inhibiter la thrombogénèse | |
EP0066908A1 (fr) | Produit antithrombogène à base de polysaccharides, procédé pour sa préparation et compositions pharmaceutiques | |
CA2293595A1 (fr) | Heparine de faible poids moleculaire modifiee inhibant les facteurs de coagulation associes au caillot | |
JP2001514630A (ja) | 抗凝血/抗血栓活性を有する硫酸化オリゴ糖類 | |
US4942156A (en) | Low molecular weight heparin derivatives having improved anti-Xa specificity | |
AU2003240190A1 (en) | Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation | |
Raake et al. | Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides | |
US4745106A (en) | Heparin derivatives having improved anti-Xa specificity | |
Onishi et al. | Anticoagulant and antiprotease activities of a heparinoid sulfated glucoside-bearing polymer | |
AU706002B2 (en) | New anticoagulants | |
EP0209924A1 (fr) | Agent antithrombotique à base de glycosaminoglycanes, procédé de préparation et composition pharmaceutique | |
Linhardt et al. | Acidic polysaccharides: their modification and potential uses | |
JP3559578B2 (ja) | プラスミン阻害剤 | |
JPH02124902A (ja) | 血液凝固抑制剤 | |
JP2002080371A (ja) | プラスミノーゲンアクチベーター活性促進剤 | |
Bianchini | Heparin and non-heparin glycosaminoglycans: future perspectives for future applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990401 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE DK ES FR GB IE IT PT SE |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RTI1 | Title (correction) |
Free format text: USE OF SULFATED POLYSACCHARIDES FOR THE TREATMENT OF A CHRONIC WOUND |
|
17Q | First examination report despatched |
Effective date: 19991008 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: JOHNSON & JOHNSON MEDICAL LIMITED. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE DK ES FR GB IE IT PT SE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20000906 Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20000913 Year of fee payment: 4 |
|
REF | Corresponds to: |
Ref document number: 69702862 Country of ref document: DE Date of ref document: 20000921 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20000925 Year of fee payment: 4 Ref country code: IE Payment date: 20000925 Year of fee payment: 4 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20000830 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2152107 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010910 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010910 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010911 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010911 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
EUG | Se: european patent has lapsed |
Ref document number: 97939097.8 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20021011 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20090521 AND 20090527 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20110907 Year of fee payment: 15 Ref country code: PT Payment date: 20110909 Year of fee payment: 15 Ref country code: FR Payment date: 20110922 Year of fee payment: 15 Ref country code: DE Payment date: 20110907 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20110913 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20130311 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120910 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130311 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120910 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130403 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120910 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121001 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69702862 Country of ref document: DE Effective date: 20130403 |